Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-08-30
2010-11-02
Vivlemore, Tracy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500
Reexamination Certificate
active
07825101
ABSTRACT:
In various aspects and embodiments the invention provides methods and reagents for controlling gene expression, and for treating disorders and diseases. Embodiments provide methods and reagents specifically for the regulation of MLCK expression and for the use thereof in treating disorders and diseases. Various embodiments provide methods and reagents for specifically down regulating the expression of MLCK-L more efficiently than that of MLCK-S, and for the use thereof in treating disorders and diseases. Embodiments provide siNA for the same, particularly siRNAs. Various of the embodiments are useful for the treatment of inflammatory disorders and diseases, including, for one example in this regard, Asthma.
REFERENCES:
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2005/0261196 (2005-11-01), Turner et al.
patent: 2006/0058255 (2006-03-01), Chen et al.
Lazar et al. Genomics 1999, vol. 57, pp. 256-267.
Bass Nature 2001, vol. 411, pp. 428-429.
Tinsley et al. Trends in Pharmacological Sciences 2004, vol. 25, pp. 64-66.
Clayburgh, D.R, et al., A differentiation-dependent splice variant of myosin light chain kinase, MLCK1, regulates epithelial tight junction permeability, J. Biol. Chem., Dec. 31, 2004, vol. 279, No. 53, pp. 55506-55513.
Kim Min Tae, et al., Involvement of calmodulin and myosin light chain kinase in activation of mTRPC5 expressed in HEK cells. Amer. J Physiol.—Cell Physiol., Apr. 2006, vol. 290, No. 4, pp. C1031-C1040.
Wainwright, M.S., et al., Protein kinase involved in lung injury susceptibility: evidence from enzyme isoform genetic knockout and in vivo inhibitor treatment, Proc. Nat. Acad. Sci. USA, May 13, 2003, vol. 100, No. 10, pp. 6233-6238.
Gao Li, et al., Novel polymorphisms in the myosin light chain kinase gene confer risk for acute lung injury, Amer. J. Resp. Cell and Mol. Biol., Apr. 2006, vol. 34, No. 4, pp. 487-495.
Bonetta, L., et al., RNAi: Silencing never sounded better, Nature Methods, Oct. 2004, vol. 1, No. 1, pp. 79-85.
Malik Asrar
Mehta Dolly
Siddiqui Shahid S.
Hofmeister Todd S.
Polsinelli Shughart PC
Scott, Jr. Teddy
The Board of Trustees of the University of Illinois
Vivlemore Tracy
LandOfFree
Modulation of MLCK-L expression and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of MLCK-L expression and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of MLCK-L expression and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4194253